Vb-111-70/Gog-3018- A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study Of Ofranergene Obadenovec (Vb-111) Combined With Paclitaxel Vs. Paclitaxel Combined With Placebo For The Treatment Of Recurrent Platinum-Resistant Ovarian Cancer
Posted Date: Oct 15, 2019
- Investigator: Thomas Herzog
- Specialties: Cancer, Ovarian Cancer
- Type of Study: Drug
The goal of this study is to evaluate the safety, tolerability, and efficacy of the combination of intravenous administration of VB-111 and paclitaxel compared to placebo and paclitaxel in patients with platinum resistant ovarian cancer as measured by overall survival (OS).
Criteria:
To Be Eligible: 18 Yrs Of Age Or Older, Female, Diagnosed With Epithelial Ovarian Cancer, Life Expectency >/= 12 Weeks, Nonpregnant/Nonbreastfeeding, No Prior Radiotherapy To Pelvis Or Abdomen, No Other Uncontrolled Active Infection Or Illness
Keywords:
Ovarian Cancer
For More Information:
Uccc Cancer Center
513-584-7698
cancer@uchealth.com